Score Overview
Explore the 2021 public Archive ranking →
Where Sanofi ADR has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- SNY
2013: 17.8% · 2021: 54.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 40.74 | — |
1 Year2025-09-29 | $ 43.25 | -5.80% |
5 Years2021-09-29 | $ 38.98 | 4.52% |
10 Years2016-09-29 | $ 25.06 | 62.58% |
20 Years2006-09-29 | $ 19.58 | 108.05% |
All Time2002-07-01 | $ 12.19 | 234.20% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2002-07-01 |
|---|---|---|---|---|---|---|
| Price | $ 40.74 | $ 43.25 | $ 38.98 | $ 25.06 | $ 19.58 | $ 12.19 |
| Return | — | -5.80% | 4.52% | 62.58% | 108.05% | 234.20% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in EUR
| Year | |||
|---|---|---|---|
| TTM | € 48.91B | € 3.95B | € 6.35B |
| 2025 | € 46.71B | € 7.81B | € 8.46B |
| 2024 | € 44.28B | € 5.56B | € 7.92B |
| 2023 | € 41.61B | € 5.40B | € 8.71B |
| 2022 | € 40.56B | € 8.37B | € 12.73B |
| 2021 | € 39.17B | € 6.22B | € 10.09B |
| 2020 | € 37.36B | € 12.29B | € 13.91B |
| 2019 | € 37.63B | € 2.75B | € 9.85B |
| 2018 | € 35.67B | € 4.30B | € 7.12B |
| 2017 | € 36.22B | € 8.41B | € 10.31B |
| 2016 | € 34.69B | € 4.70B | € 10.38B |
| 2015 | € 34.86B | € 4.28B | € 9.24B |
| 2014 | € 31.99B | € 4.39B | € 7.55B |
| 2013 | € 31.29B | € 3.71B | € 8.44B |
| 2012 | € 35.95B | € 4.88B | € 6.55B |
| 2011 | € 35.05B | € 5.64B | € 4.29B |
| 2010 | € 34.03B | € 5.46B | € 6.51B |
| 2009 | € 30.74B | € 5.26B | € 4.96B |
| 2008 | € 28.81B | € 3.85B | € 4.62B |
| 2007 | € 29.20B | € 5.26B | € 1.79B |
| 2006 | € 29.48B | € 4.00B | € 1.26B |
| 2005 | € 28.49B | € 2.25B | € 1.56B |
| 2004 | € 15.72B | € 1.98B | € 2.48B |
| 2003 | € 8.03B | € 2.07B | € 3.37B |
| IPO2002 | € 7.45B | € 1.76B | € 3.09B |
Sanofi ADR fundamental performance
Between 2020 and 2025, revenue grew from € 37.36B to € 46.71B and net income declined from € 12.29B to € 7.81B. Revenue increased in every one of those 5 years; net income in 3.
Across Sanofi ADR's full reported history, from 2002 to 2025, revenue grew from € 7.45B to € 46.71B and net income grew from € 1.76B to € 7.81B. Revenue increased in 75% of the years measured; net income in 58%.
Sanofi ADR currently holds a 20-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.
Membership
Continue SNY’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
